We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

260 hedge funds and large institutions have $3.09B invested in Axsome Therapeutics in 2024 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 96 increasing their positions, 75 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 26

28% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 75

7% more funds holding

Funds holding: 244 → 260 (+16)

1% less capital invested

Capital invested by funds: $3.12B → $3.09B (-$30.4M)

1.03% less ownership

Funds ownership: 82.88% → 81.84% (-1%)

25% less call options, than puts

Call options by funds: $49.5M | Put options by funds: $66.4M

31% less funds holding in top 10

Funds holding in top 10: 13 → 9 (-4)

Holders
260
Holders Change
+16
Holders Change %
+6.56%
% of All Funds
3.75%
Holding in Top 10
9
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-30.77%
% of All Funds
0.13%
New
45
Increased
96
Reduced
75
Closed
26
Calls
$49.5M
Puts
$66.4M
Net Calls
-$16.9M
Net Calls Change
-$54.8M

Top Buyers

1
Macquarie Group
Macquarie Group
Australia
+$56.5M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.7M
3
DTC
Deep Track Capital
Connecticut
+$25.6M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$23.5M
5
EAM
Eagle Asset Management
Florida
+$19M

Top Sellers

1
BI
BVF Inc
California
-$158M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$38.5M
3
Pictet Asset Management
Pictet Asset Management
Switzerland
-$29.1M
4
TCM
Tang Capital Management
California
-$25.5M
5
Morgan Stanley
Morgan Stanley
New York
-$24.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
76
UBS Group
Switzerland
$4.89M +$1.78M +21,195 +53%
Swiss National Bank
77
Swiss National Bank
Switzerland
$4.83M – – –
SSA
78
Schonfeld Strategic Advisors
New York
$4.8M -$3.92M -46,660 -44%
Schroder Investment Management Group
79
Schroder Investment Management Group
United Kingdom
$4.65M – – –
RhumbLine Advisers
80
RhumbLine Advisers
Massachusetts
$4.17M +$136K +1,620 +3%
BWP
81
Baldwin Wealth Partners
Massachusetts
$3.97M +$58.8K +700 +1%
HS
82
HighVista Strategies
Massachusetts
$3.87M -$1.15M -13,736 -22%
CS
83
Credit Suisse
Switzerland
$3.49M -$30.4K -362 -0.8%
MOACM
84
Mutual of America Capital Management
New York
$3.32M +$591K +7,042 +20%
WP
85
WMS Partners
Maryland
$3.25M -$839K -10,000 -20%
Susquehanna International Group
86
Susquehanna International Group
Pennsylvania
$3.14M +$2.23M +26,558 +208%
NIP
87
Nicholas Investment Partners
California
$2.94M -$3.85M -45,829 -55%
SCM
88
Superstring Capital Management
New York
$2.92M +$1.71M +20,428 +126%
SEI Investments
89
SEI Investments
Pennsylvania
$2.85M +$226K +2,697 +8%
Group One Trading
90
Group One Trading
Illinois
$2.83M +$1.72M +20,543 +138%
State of New Jersey Common Pension Fund D
91
State of New Jersey Common Pension Fund D
New Jersey
$2.7M -$350K -4,172 -11%
SFG
92
SVB Financial Group
Texas
$2.7M – – –
AA
93
ALPS Advisors
Colorado
$2.67M +$78.5K +935 +3%
Legal & General Group
94
Legal & General Group
United Kingdom
$2.62M -$12.6K -150 -0.5%
AA
95
AlphaCentric Advisors
Puerto Rico
$2.59M +$2.73M +32,500 New
CM
96
Castleark Management
Illinois
$2.57M +$2.7M +32,200 New
DekaBank Deutsche Girozentrale
97
DekaBank Deutsche Girozentrale
Germany
$2.53M – – –
California State Teachers Retirement System (CalSTRS)
98
California State Teachers Retirement System (CalSTRS)
California
$2.49M -$163K -1,941 -6%
IHAM
99
Integral Health Asset Management
New York
$2.39M +$2.52M +30,000 New
Carson Wealth (CWM LLC)
100
Carson Wealth (CWM LLC)
Nebraska
$2.36M -$737K -8,776 -23%
2 3
4
5 6

AXSM Hedge Fund Activity: Q1 2024 in Review

260 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2024, worth a combined $3.09B — down 0.98% from $3.12B a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new AXSM positions and 26 closed out — a net gain of 19 holders — while 96 added to existing stakes and 75 trimmed.

The largest buyer was Macquarie Group, adding an estimated $56.5M. The largest seller was BVF Inc, exiting entirely with an estimated $158M sold.

  • 260 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2024, up from 244 in Q4 2023.
  • Funds reported $3.09B of Axsome Therapeutics stock for Q1 2024, down 0.98% quarter-over-quarter.
  • 45 funds opened new Axsome Therapeutics positions in Q1 2024 and 26 closed out, a net change of +19 holders.
  • The largest Axsome Therapeutics buyer in Q1 2024 was Macquarie Group, an estimated $56.5M added.
  • The largest Axsome Therapeutics seller in Q1 2024 was BVF Inc, an estimated $158M sold.

Based on aggregated 13F filings for Q1 2024.